Clinical benefits and economic cost-savings of remote electrical neuromodulation (REN) for migraine prevention

References

• Steiner TJ, Stovner LJ. Global epidemiology of migraine and its implications for public health and health policy. Nat Rev Neurol. 2023;19(2):109–117.
   PubMedGoogle Scholar
• Stovner LJ, Hagen K, Linde M, et al. The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain. 2022;23(1):34.
   PubMed Web of Science ®Google Scholar
• Agosti R. Migraine burden of disease: from the patient’s experience to a socio-economic view. Headache J Head Face Pain. 2018;58:17–32.
   PubMed Web of Science ®Google Scholar
• Yucel A, Thach A, Kumar S, et al. Estimating the economic burden of migraine on US employers. Am J Manag Care. 2020;26:e403–8.
   Web of Science ®Google Scholar
• Bonafede M, Sapra S, Shah N, et al. Direct and indirect healthcare resource utilization and costs among migraine patients in the United States. Headache. 2018;58(5):700–714.
   PubMed Web of Science ®Google Scholar
• Hawkins K, Wang S, Rupnow MF. Indirect cost burden of migraine in the United States. J Occup Environ Med. 2007;49(4):368–374.
   PubMed Web of Science ®Google Scholar
• López Martínez M, del V, Pareja Román J, et al. Chronic migraine with medication overuse: clinical pattern and evolution from a retrospective cohort in seville, Spain. SN Compr Clin Med. 2020;2(9):1514–1525.
   Google Scholar
• Lipton RB, Hamelsky SW, Kolodner KB, et al. Migraine, quality of life, and depression: a population-based case-control study. Neurology. 2000;55(5):629–635.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Liberman JN, Kolodner KB, et al. Migraine headache disability and health-related quality-of-life: a population-based case-control study from England. Cephalalgia. 2003;23(6):441–450.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343–349.
   PubMed Web of Science ®Google Scholar
• Ashina M, Buse DC, Ashina H, et al. Migraine: integrated approaches to clinical management and emerging treatments. Lancet. 2021;397(10283):1505–1518.
   PubMed Web of Science ®Google Scholar
• Devine J, Hadsall R, Cline R, et al. Effect of daily migraine prevention on health care utilisation in an insured patient population. J Headache Pain. 2007;8(2):105–113.
   PubMedGoogle Scholar
• Starling AJ, Dodick DW. Best practices for patients with chronic migraine: burden, diagnosis, and management in primary care. Mayo Clin Proc. 2015;90(3):408–414.
   PubMed Web of Science ®Google Scholar
• Wertz DA, Quimbo RM, Yaldo AZ, et al. Resource utilization impact of topiramate for migraine prevention in the managed-care setting. Curr Med Res Opin. 2009;25(2):499–503.
   PubMed Web of Science ®Google Scholar
• Láinez MJ. The effect of migraine prophylaxis on migraine-related resource use and productivity. CNS Drugs. 2009;23(9):727–738.
   Google Scholar
• Burton WN, Landy SH, Downs KE, et al. The impact of migraine and the effect of migraine treatment on workplace productivity in the United States and suggestions for future research. Mayo Clin Proc. 2009;84(5):436–445.
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Preventive migraine treatment. Continuum. 2015;21:973–989.
   PubMedGoogle Scholar
• Ailani J, Burch RC, Robbins MS, Society the B of D of the AH. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache J Head Face Pain. 2021;61(7):1021–1039.
   PubMed Web of Science ®Google Scholar
• Lewis GN, Rice DA, McNair PJ. Conditioned pain modulation in populations with chronic pain: a systematic review and meta-analysis. J Pain. 2012;13(10):936–944.
   PubMed Web of Science ®Google Scholar
• Nir RR, Yarnitsky D. Conditioned pain modulation. Curr Opin Support Palliat Care. 2015;9(2):131–137.
   PubMed Web of Science ®Google Scholar
• Nierenburg H, Vieira JR, Lev N, et al. Remote electrical neuromodulation for the acute treatment of migraine in patients with chronic migraine: an open-label pilot study. Pain Ther. 2020;9(2):531–543.
   PubMed Web of Science ®Google Scholar
• Grosberg B, Rabany L, Lin T, et al. Safety and efficacy of remote electrical neuromodulation for the acute treatment of chronic migraine: an open-label study. Pain Rep. 2021;6(4):e966.
   PubMedGoogle Scholar
• Yarnitsky D, Dodick DW, Grosberg BM, et al. Remote electrical neuromodulation (REN) relieves acute migraine: a randomized, double-blind, placebo-controlled, multicenter trial. Headache. 2019;59(8):1240–1252.
   PubMed Web of Science ®Google Scholar
• Hershey AD, Lin T, Gruper Y, et al. Remote electrical neuromodulation for acute treatment of migraine in adolescents. Headache J Head Face Pain. 2021;61(2):310–317.
   PubMed Web of Science ®Google Scholar
• Ailani J, Rabany L, Tamir S, et al. Real-World analysis of remote electrical neuromodulation (REN) for the acute treatment of migraine. Front. Pain Res. 2022;2:753736.
   Google Scholar
• VanderPluym JH, Halker Singh RB, Urtecho M, et al. Acute treatments for episodic migraine in adults: a systematic review and meta-analysis. JAMA. 2021;325(23):2357–2369.
   PubMed Web of Science ®Google Scholar
• Moisset X, Pereira B, Ciampi de Andrade D, et al. Neuromodulation techniques for acute and preventive migraine treatment: a systematic review and meta-analysis of randomized controlled trials. J Headache Pain. 2020;21(1):142.
   PubMed Web of Science ®Google Scholar
• Ailani J, Burch RC, Robbins MS, MS, Board of Directors of the American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021–1039.
   PubMed Web of Science ®Google Scholar
• Tepper SJ, Rabany L, Cowan RP, et al. Remote electrical neuromodulation for migraine prevention: a double-blind, randomized, placebo-controlled clinical trial. Headache. 2023;63(3):377–389.
   PubMed Web of Science ®Google Scholar
• Yarnitsky D, Volokh L, Ironi A, et al. Nonpainful remote electrical stimulation alleviates episodic migraine pain. Neurology. 2017;88(13):1250–1255.
   PubMed Web of Science ®Google Scholar
• Rapoport AM, Lin T. Device profile of the NerivioTM for acute migraine treatment: overview of its efficacy and safety. Expert Rev Med Devices. 2019;0:1–7.
   Google Scholar
• Wang JT, Barr CE, Goldfarb SD. Impact of chest pain on cost of migraine treatment with almotriptan and sumatriptan. Headache. 2002;42(Suppl 1):38–43.
   PubMedGoogle Scholar
• Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. The Lancet. 2021;397(10268):51–60.
   PubMed Web of Science ®Google Scholar
• Ailani J, Lipton RB, Goadsby PJ, et al. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021;385(8):695–706.
   PubMed Web of Science ®Google Scholar
• Diener H-C, Goadsby PJ, Ashina M, et al. Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: the multicentre, double-blind, randomised, sham-controlled PREMIUM trial. Cephalalgia. 2019;39(12):1475–1487.
   PubMed Web of Science ®Google Scholar
• Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425–434.
   PubMed Web of Science ®Google Scholar
• Hathway JM, Miller-Wilson L-A, Jensen IS, et al. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives. J Med Econ. 2020;23(6):581–592.
   PubMed Web of Science ®Google Scholar
• Musgrove P, Fox-Rushby J, et al. Cost-Effectiveness analysis for priority setting. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, editors. Disease control priorities dev. Ctries. 2nd ed., Washington (DC): The International Bank for Reconstruction and Development/The World Bank; 2006.
   Google Scholar
• Wang W, Gellings Lowe N, Jalali A, et al. Economic modeling of reSET-O, a prescription digital therapeutic for patients with opioid use disorder. J Med Econ. 2021;24(1):61–68.
   PubMed Web of Science ®Google Scholar
• Powering healthcare with connected intelligence – IQVIA; n.d. [cited 2022 Nov 14]. Available from: https://www.iqvia.com/.
   Google Scholar
• National employment and wage data from the Occupational Employment and Wage Statistics survey by occupation, Table 1; n.d. [cited 2022 Nov 13]. Available from: https://www.bls.gov/news.release/ocwage.t01.htm.
   Google Scholar
• Shimizu T, Sakai F, Miyake H, et al. Disability, quality of life, productivity impairment and employer costs of migraine in the workplace. J Headache Pain. 2021;22(1):29.
   PubMed Web of Science ®Google Scholar
• STATISTICAL BRIEF #517: expenses for office-based physician visits by specialty and insurance type, 2016; n.d. [cited 2022 Nov 13]. Available from: https://www.meps.ahrq.gov/data_files/publications/st517/stat517.shtml.
   Google Scholar
• Doctors’ charges, physician prices, average cost, anesthesia. Consum Health Rat; n.d. [cited 2022 Nov 13]. Available from: https://consumerhealthratings.com/healthcare_category/doctors-charges-physician-prices-average-cost-anesthesia/.
   Google Scholar
• Collins JJ, Baase CM, Sharda CE, et al. The assessment of chronic health conditions on work performance, absence, and total economic impact for employers. J Occup Environ Med. 2005;47(6):547–557.
   PubMed Web of Science ®Google Scholar